CONCERTA methylphenidate hydrochloride 36mg extended-release tablets (Switzerland)
Section 19A approved medicine
CONCERTA methylphenidate hydrochloride 36mg extended-release tablets (Switzerland)
Section 19A approval holder
Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Phone
1300 788 261
Approved until
Status
Current
Medicines in short supply/unavailable
CONCERTA methylphenidate hydrochloride 36mg modified release tablet bottle - ARTG 93863
METHYLPHENIDATE-TEVA XR methylphenidate hydrochloride 36 mg modified release tablet bottle - ARTG 370900
METHYLPHENIDATE-TEVA XR methylphenidate hydrochloride 36 mg modified release tablet bottle - ARTG 370900
Indication(s)
CONCERTA is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Treatment should be commenced by a specialist.
Images
